353 related articles for article (PubMed ID: 21226635)
1. Strategies to manage antifungal drug resistance.
Tseng HK; Perfect JR
Expert Opin Pharmacother; 2011 Feb; 12(2):241-56. PubMed ID: 21226635
[TBL] [Abstract][Full Text] [Related]
2. Emerging moulds: epidemiological trends and antifungal resistance.
Miceli MH; Lee SA
Mycoses; 2011 Nov; 54(6):e666-78. PubMed ID: 21672045
[TBL] [Abstract][Full Text] [Related]
3. Current status of antifungal resistance and its impact on clinical practice.
Alcazar-Fuoli L; Mellado E
Br J Haematol; 2014 Aug; 166(4):471-84. PubMed ID: 24749533
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.
Kanafani ZA; Perfect JR
Clin Infect Dis; 2008 Jan; 46(1):120-8. PubMed ID: 18171227
[TBL] [Abstract][Full Text] [Related]
5. Role of antifungal susceptibility testing in patient management.
Forrest G
Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
[TBL] [Abstract][Full Text] [Related]
6. Recent advances and challenges in the treatment of invasive fungal infections.
Shao PL; Huang LM; Hsueh PR
Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.
Sun HY; Singh N
Int J Antimicrob Agents; 2010 Mar; 35(3):211-8. PubMed ID: 20036518
[TBL] [Abstract][Full Text] [Related]
8. Antifungal drug resistance of pathogenic fungi.
Kontoyiannis DP; Lewis RE
Lancet; 2002 Mar; 359(9312):1135-44. PubMed ID: 11943280
[TBL] [Abstract][Full Text] [Related]
9. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
10. [How do fungal infections "escape" treatment? Resistance and resistance mechanisms].
Morschhäuser J
Pharm Unserer Zeit; 2003; 32(2):124-8. PubMed ID: 12677965
[No Abstract] [Full Text] [Related]
11. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections.
Lewis RE
Am J Ther; 2012 Jan; 19(1):51-63. PubMed ID: 21248618
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility testing in fungi: a global perspective on a variety of methods.
Lass-Flörl C; Perkhofer S; Mayr A
Mycoses; 2010 Jan; 53(1):1-11. PubMed ID: 20078786
[TBL] [Abstract][Full Text] [Related]
13. Prevention of fungal infections in the immunocompromised host.
Mahfouz T; Anaissie E
Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882
[TBL] [Abstract][Full Text] [Related]
14. Update on antifungal agents for paediatric patients.
Groll AH; Tragiannidis A
Clin Microbiol Infect; 2010 Sep; 16(9):1343-53. PubMed ID: 20678177
[TBL] [Abstract][Full Text] [Related]
15. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
16. Management of invasive fungal infections: a role for polyenes.
Chandrasekar P
J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment of invasive fungal infections.
Mukherjee PK; Sheehan DJ; Hitchcock CA; Ghannoum MA
Clin Microbiol Rev; 2005 Jan; 18(1):163-94. PubMed ID: 15653825
[TBL] [Abstract][Full Text] [Related]
18. Changing epidemiology of systemic fungal infections.
Richardson M; Lass-Flörl C
Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126
[TBL] [Abstract][Full Text] [Related]
19. Combination antifungal therapy: the new frontier.
Vazquez JA
Future Microbiol; 2007 Apr; 2(2):115-39. PubMed ID: 17661650
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.
Cecil JA; Wenzel RP
Expert Rev Hematol; 2009 Jun; 2(3):237-54. PubMed ID: 21082966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
